PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety DisordersPosted by MMP News AuthorOn June 21, 2023

BOSTON–(BUSINESS WIRE)–PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders



Source link